Orthofix International N.v Stock News

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced that President and Chief Executive Officer

Orthofix Medical Inc. (NASDAQ:OFIX ) Q2 2022 Earnings Conference Call August 5, 2022 8:30 AM ET Company Participants Alexa Huerta – Senior Director-Investor Relations Jon Serbousek – President and

Orthofix (OFIX) delivered earnings and revenue surprises of 14.29% and 0.57%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Orthofix (OFIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Orthofix Medical Inc. (NASDAQ:OFIX ) Q1 2022 Earnings Conference Call May 6, 2022 8:30 AM ET Company Participants Jon Serbousek – Director, President and Chief Executive Officer Doug Rice – Chief

Orthofix (OFIX) delivered earnings and revenue surprises of -155.56% and 1.64%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

There's a reason why it's so cheap, but it isn't a deal breaker.

Stocks like Orthofix Medical Inc. (OFIX), Stryker Corporation (SYK) and NuVasive, Inc. (NUVA) are likely to gain enormously from developments in the orthopedic space.

Medical device company, Orthofix Medical <>, announced on Monday that the U.S

The shares of medical device and biologics company, Orthofix Medical <>, has risen sharply after Stifel upgraded it to Buy from Hold, citing the prospects in growth and margins

The consensus price target hints at a 46.7% upside potential for Orthofix (OFIX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate

Orthofix Medical Inc. (OFIX) CEO Jon Serbousek on Q4 2021 Results - Earnings Call Transcript

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX) today reported its financial results for the fourth quarter and fiscal year ended December 31, 2021. Net sales for the fourth quarter were $125.1 million, earnings (loss) per share (“EPS”) was $(1.65) and adjusted EPS was $0.27. For fiscal year 2021, net sales were $464.5 million, EPS was $(1.95) and adjusted EPS was $0.86. “Despite the headwinds our industry faced throughout the year, we delivered double digit revenue grow

Orthofix (OFIX) delivered earnings and revenue surprises of 107.69% and 0.13%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?